II.AbstractThe tumor immune microenvironment (TIME) of breast cancer is a known source of tumor heterogeneity and it has been increasingly recognized as having a role in the course of disease. In the present study, we used a computational approach to dissect the landscape of TIME states among TCGA breast cancer patients. Our central hypothesis is that the pre-existing TIME states represent a dimension which is informative about the prognosis and the response to immunotherapy. In order to test this hypothesis, we first classified breast cancer patients according to their primary TIME status. Next, we describe a TIME-based classification with prognostic value for overall survival among the TCGA patients. We further demonstrated that absolute quantification of mast cells, M0 macrophages, CD8 T cells and neutrophils were predictive of overall survival. In order to identify the TIME states which, predict response to immune checkpoint blockade, we performed a similar analysis of 11 different mouse models of primary invasive breast carcinoma that were subsequently treated with immune checkpoint inhibitor (ICI) therapy. These analyses revealed that the TIME content of M1 macrophages, monocytes and resting dendritic cells were predictive of sensitivity to ICI therapy. Taken together, these results indicate that (1) the landscape of human primary TIME states is diverse and can identify patients with more or less aggressive disease and (2) that pre-existing TIME states may be able to identify patients, of all molecular subtypes of breast cancer, who are good candidates for ICI therapy.
I disease, 28,729 (88%) received AC and only 3,876 (12%) received NAC. Complete response (ypT0/isN0) (pCR) was achieved in 7,302 of 30,527 patients (24%). Crude death rate was significantly different in AC, NAC-pCR and NAC-non-pCR: 12.7%, 5.5% and 26.9% respectively (p < 0.01). Overall, NAC non-pCR was significantly associated with worse OS. For patients with cStage IIA disease, NAC did not confer OS benefits.CONCLUSION: NAC-non-pCR is associated with worse unadjusted outcomes as expected. However, NAC did not appear to improve outcomes in patients with cStage IIA eTNBC. Future work to elucidate the clinical benefits of emerging novel NAC strategies in eTNBC will be of interest.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.